FGF23 and left ventricular hypertrophy: Our prior research, focusing on FGF23 as a biomarker for cardiac impairment, revealed cardiac changes in pediatric CKD patients, particularly highlighting left ventricular hypertrophy and impaired systolic function among those with CKD stage 2 and higher [12].